Tardive Dyskinesia: A 2026 PMHNP Screening Playbook

Key takeaways for tardive dyskinesia screening

Why tardive dyskinesia screening matters in 2026

One in four. That is the share of patients on long-term antipsychotic therapy who carry tardive dyskinesia. Any tardive dyskinesia screening program will eventually flag them. Most have never been formally examined for it.

Tardive dyskinesia is a slow-motion clinical problem. Symptoms creep in months or years after starting the antipsychotic. They fluctuate from visit to visit, and the same medication that caused them can partially mask them. The patient often adjusts to the movements before the prescriber names them.

For PMHNPs, the practical question is not whether TD will appear in the panel — it will. The question is whether it gets caught at AIMS-score 4 or AIMS-score 14. It is also whether the chart shows a documented screening cadence the day a patient or family raises a concern.

This playbook covers four things. It walks through the prevalence math that should set screening cadence, the AIMS exam done in under 10 minutes, the four common missteps that delay a TD diagnosis, and the VMAT2 inhibitor decision when treatment is indicated.

The 2026 tardive dyskinesia screening prevalence picture

A 2017 meta-analysis in the Journal of Clinical Psychiatry pooled 41 studies and 11,493 patients on antipsychotics and put global TD prevalence at 25.3%. The breakdown matters more than the headline number. Patients on first-generation antipsychotics had a TD prevalence of 30.0%. Patients on second-generation antipsychotics had a TD prevalence of 20.7%.

The split widens with age. In adults the per-year incidence on first-generation antipsychotics is about 5%; in adults over 55 the incidence is closer to 25 to 30% per year. A 3-year prospective study put the cumulative incidence on first-generation agents at 23% at 1 year, 42% at 2 years, and 57% at 3 years in older adults.

First- vs second-generation antipsychotic risk

Second-generation agents reduce the risk but do not eliminate it. Risperidone and paliperidone — high D2 occupancy at standard doses — sit at the higher end of the second-generation TD risk profile. Aripiprazole and brexpiprazole, partial agonists, sit lower. Quetiapine and clozapine are the lowest-risk second-generation choices, and clozapine is the only antipsychotic with prospective evidence of TD improvement on switching.

“The 25 percent prevalence number is the one that should change PMHNP behavior. If a quarter of a panel on long-term antipsychotics carries the condition, an annual AIMS exam is not a special procedure. It is the standard of care. It should appear in the chart whether the score is zero or twelve,” says Lindsay Hill, DNP, PMHNP-BC.

Why these numbers matter at the bedside

The clinical reason to know these numbers cold is not academic. It is to set a defensible screening cadence. It also means choosing the antipsychotic with the right risk profile from the start, not after a movement disorder appears.

Who is actually at risk — and how often to screen

The 2020 APA schizophrenia practice guideline pushed TD screening cadence into a clearer two-tier structure. A structured AIMS examination at antipsychotic initiation, every 6 months in higher-risk patients, and every 12 months in everyone else on a dopamine receptor blocking agent. A brief inquiry about involuntary movements at every clinical encounter is recommended on top of the structured exams.

Higher-risk patients: age 55 and older; female sex; mood disorders rather than primary psychotic disorders; prior drug-induced parkinsonism; cumulative antipsychotic exposure greater than 5 years; current or prior first-generation antipsychotic; African ancestry; comorbid diabetes or substance use disorder; and current use of metoclopramide or prochlorperazine, both of which are dopamine receptor blockers that count toward cumulative exposure even though they are not labeled “antipsychotic.”

A documented baseline AIMS at the start of any new antipsychotic is the single most important entry in the chart. Without it, every subsequent finding is impossible to attribute. With it, the trajectory is legible. The same logic applies when a patient is transferred in already on a long-standing antipsychotic regimen — the first visit gets a baseline AIMS regardless of how stable the medication has been elsewhere.

For PMHNPs running 30-minute medication-management visits, the cadence question often becomes a workflow question. Build the AIMS into a recurring template. Code it as a CPT add-on or document it inside the evaluation and management note. That keeps it from becoming an “if I have time” task.

Tardive dyskinesia screening: running an efficient AIMS exam in 30 minutes

The AIMS examination has 12 items, but the dyskinesia score that matters in practice is the sum of items 1 through 7 — facial and oral movements, extremity movements, and trunk movements. Items 8 through 10 grade severity, incapacitation, and the patient’s awareness. Items 11 and 12 capture dental status, which can mimic oral dyskinesias.

The 7-step AIMS sequence for tardive dyskinesia screening

The 7-step procedural sequence takes under 10 minutes when done in order. Ask the patient about anything in the mouth and remove gum or dentures if loose. Have the patient sit in a hard chair without arms, hands on knees, feet flat. Observe the whole body at rest. Ask the patient to open the mouth, then protrude the tongue, twice. Have the patient tap thumb to fingers as fast as possible, each hand separately. Flex and extend the arms one at a time. Have the patient stand and walk a few steps, then return to seat. Score each item zero to four.

Two practical AIMS tips

Two practical tips. First, the activated maneuvers — hand tapping, walking — are designed to bring out latent movements the patient is unconsciously suppressing. Time spent on these matters more than time spent at rest. Second, telehealth AIMS is feasible with three accommodations. Use adequate lighting and framing that captures the upper body and full face. Ask the patient to stand and walk while keeping the camera in view. Document the modality.

What an AIMS-positive screen looks like

A score of 2 or higher in any of items 1 through 7 is the screening threshold most TD specialists use to trigger formal evaluation. A total dyskinesia score (items 1–7) of 6 or higher meets the entry criteria of the deutetrabenazine pivotal trials and is a reasonable threshold for considering VMAT2 treatment.

What most PMHNPs get wrong about tardive dyskinesia screening

The first misstep is screening reactively. The chart that says “no involuntary movements observed” with no AIMS score and no procedural notation is functionally a non-screen. When a patient or family later asks how long the movements have been there, the answer should be a series of dated AIMS totals, not a clinical impression.

Confusing TD with drug-induced parkinsonism

The second is confusing TD with drug-induced parkinsonism, akathisia, or anticholinergic withdrawal dyskinesia. TD movements are typically choreiform — quick, irregular, non-purposeful — and most often start in the lower face and tongue. Parkinsonism is rhythmic, slower, and bradykinetic. Akathisia is an internal restlessness driving repetitive motor behavior. Anticholinergic withdrawal dyskinesia appears in the days to weeks after benztropine or trihexyphenidyl is reduced or stopped and may not be true TD at all.

The reflex to stop or lower the antipsychotic

The third is stopping or rapidly lowering the antipsychotic when TD is identified. Antipsychotic withdrawal can transiently worsen the movements and risks psychiatric decompensation. The 2024 American Academy of Neurology guidance — and the consensus across the TD specialty — is to continue the lowest effective antipsychotic dose, add a VMAT2 inhibitor, and consider a switch to a lower-risk agent like clozapine or quetiapine in parallel for select patients.

Forgetting non-antipsychotic dopamine blockers

The fourth is overlooking the non-antipsychotic dopamine blockers. Metoclopramide for gastroparesis, prochlorperazine for migraine and nausea, and promethazine in higher cumulative doses all carry TD risk and all count toward the exposure clock. The medication reconciliation that asks only about “psychiatric medications” misses the exact agents most likely to be flying under the radar.

VMAT2 inhibitors after positive tardive dyskinesia screening: when and which one

Two FDA-approved VMAT2 inhibitors are first-line: valbenazine (Ingrezza) and deutetrabenazine (Austedo XR). Both block presynaptic vesicular monoamine transporter type 2, lowering striatal dopamine release. Both produced roughly 30 to 40 percent reductions in total AIMS dyskinesia score at week 12 in pivotal trials, with response rates — defined as ≥50 percent AIMS reduction — in the 35 to 45 percent range.

Dosing valbenazine and deutetrabenazine

Valbenazine starts at 40 mg orally once daily for 1 week, then 80 mg once daily, with a 60 mg dose available for tolerability. Deutetrabenazine XR starts at 12 mg once daily, increased weekly by 6 mg to a target dose typically between 24 and 36 mg daily, with a 48 mg ceiling. Both are once-daily in their current formulations. Both are pregnancy category C-equivalent and both can prolong QTc — get a baseline ECG when other QTc-relevant medications are on board.

Choosing between the two agents

Choosing between the two often comes down to insurance and metabolizer status. Valbenazine is metabolized partly through CYP3A4 and CYP2D6, with dose adjustment for strong inhibitors and for poor CYP2D6 metabolizers. Deutetrabenazine has a hard daily ceiling of 36 mg in poor CYP2D6 metabolizers and with strong CYP2D6 inhibitors. Both require prior authorization in nearly every commercial and Medicaid plan, and the manufacturer hubs handle the paperwork lift effectively.

Monitoring cadence on a VMAT2 inhibitor

The monitoring cadence on a VMAT2 inhibitor: AIMS at baseline before initiation, AIMS at weeks 4, 8, and 12, then every 3 months once stable. Watch for somnolence, akathisia (paradoxically — VMAT2 inhibitors can cause it), parkinsonism, and depression or suicidality, which carry a labeling caution. Check QTc at baseline and after dose increases when other QTc-relevant medications are co-prescribed.

Stopping a VMAT2 inhibitor

Discontinuation usually involves a slow taper rather than an abrupt stop. The TD movements typically return within 2 to 6 weeks of discontinuation, sometimes worse than at baseline before the medication started.

The bottom line. Tardive dyskinesia is a 25 percent problem hiding inside every long-term antipsychotic panel, and the difference between catching it at AIMS-score 4 and AIMS-score 14 is almost entirely a function of whether a structured screening cadence is on the chart.

The next step is not the VMAT2 prescription. It is the baseline AIMS at the next medication-management visit, a documented every-6-or-12-month follow-up cadence in the EHR template, and a one-page summary of the four common missteps for the rest of the team.

This content is for educational purposes and does not replace individualized clinical judgment or supervision.